Melbourne, Aug 15, 2011 (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the “Clinical Science: Special Reports” session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.
